Adial Pharmaceuticals announces annual shareholder meeting
Reuters2026/08/11 10:08- Adial Pharmaceuticals will hold its 2026 annual stockholder meeting in September 2026 in Charlottesville, Virginia.
- Votes are scheduled on issuing 12,930,617 common shares from conversion of Series A Non-Voting Convertible Preferred Stock tied to the Azora acquisition.
- Other items include approval to issue up to 1,177,782 shares from assumed Azora options, up to 11,780,948 shares from Initial Closing Pre-Funded Warrants.
- Stockholders will also vote on issuing up to 23,561,896 shares from Milestone Pre-Funded Warrants and Milestone Incentive Warrants, plus raising authorized common shares to 500,000,000.
- Additional proposals cover issuing up to 552,940 shares from Series F warrants, amending the 2017 equity plan, adopting 2026 equity plan and 2026 employee stock purchase plan.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Telstra announces annual shareholder meeting notice
Basecat's market cap reached a peak of 43.6 million USD this morning, with a 24-hour increase of 84.74%.
TEL Venture Capital invests in Japan’s Advance Composite
AI success leads to deflation, failure shifts focus to safety! Apollo Chief Economist: Regardless of the scenario, U.S. Treasury yields will decline in 2027.
Torsten Slok believes that successful AI commercialization will lead to a large-scale deflationary effect, resulting in declining interest rates; if the AI bubble bursts, the Nasdaq could plummet by 50%, prompting a surge of safe-haven funds into US Treasuries and causing yields to drop sharply as well. The next six months are a key window; market narratives are expected to shift from "inflation + fiscal deficit" to the success or failure of AI. Current high interest rates may be on the eve of a turning point.
Crypto prices
More
